ZyVersa Therapeutics, Inc. financial data

Symbol
ZVSA on Nasdaq
Industry
Pharmaceutical Preparations
Location
217 W. Main Street, Somerville, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
Larkspur Health Acquisition Corp. (to 12/9/2022)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 17.6 % -44.2%
Debt-to-equity 118 % +354%
Return On Equity -225 % -56.4%
Return On Assets -103 % +9.47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.34M shares -94.6%
Common Stock, Shares, Outstanding 1.07M shares -97.5%
Entity Public Float 5.6M USD -92.7%
Common Stock, Value, Issued 107 USD -97.5%
Weighted Average Number of Shares Outstanding, Basic 988K shares +916%
Weighted Average Number of Shares Outstanding, Diluted 988K shares +916%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.92M USD -42.8%
General and Administrative Expense 7.71M USD -23.8%
Operating Income (Loss) -21.8M USD +77%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -21.9M USD +76.8%
Income Tax Expense (Benefit) 9.71K USD
Net Income (Loss) Attributable to Parent -21.3M USD +74.9%
Earnings Per Share, Basic 1.74K USD/shares +91.9%
Earnings Per Share, Diluted 1.74K USD/shares +91.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 390K USD -80.5%
Property, Plant and Equipment, Net 1.73K USD -85.7%
Operating Lease, Right-of-Use Asset 7.84K USD -92%
Intangible Assets, Net (Excluding Goodwill) 30.8M USD
Goodwill 11.9M USD
Other Assets, Noncurrent 18.6M USD
Assets 19.4M USD -40.9%
Accounts Payable, Current 9.28M USD +4.35%
Accrued Liabilities, Current 2.26M USD -18.7%
Liabilities, Current 11.5M USD -1.41%
Deferred Income Tax Liabilities, Net 855K USD -40.7%
Liabilities 12.4M USD -5.72%
Retained Earnings (Accumulated Deficit) -111M USD -23.7%
Stockholders' Equity Attributable to Parent 7.03M USD -64.3%
Liabilities and Equity 19.4M USD -40.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.78M USD +17.7%
Net Cash Provided by (Used in) Financing Activities 2.67M USD
Common Stock, Shares Authorized 250M shares +127%
Common Stock, Shares, Issued 1.07M shares -97.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.1M USD +76.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 123K USD -92.2%
Deferred Tax Assets, Valuation Allowance 14.1M USD -5.12%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 17.9M USD +24.5%
Depreciation 2.6K USD 0%
Lessee, Operating Lease, Liability, to be Paid 8.66K USD -92%
Property, Plant and Equipment, Gross 52K USD 0%
Operating Lease, Liability, Current 8.66K USD -92%
Lessee, Operating Lease, Liability, to be Paid, Year One 8.7K USD -92.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 48 USD -98.8%
Deferred Tax Assets, Operating Loss Carryforwards 9.97M USD +49.5%
Deferred Federal Income Tax Expense (Benefit) -152K USD
Preferred Stock, Shares Authorized 1M shares 0%
Operating Lease, Payments 8.66K USD -64.3%
Additional Paid in Capital 118M USD +7.9%
Deferred Tax Assets, Net of Valuation Allowance 3.79M USD -73.6%
Share-based Payment Arrangement, Expense 842K USD -11.6%
Deferred State and Local Income Tax Expense (Benefit) -34.8K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%